CYCLACEL PHARMACEUTICALS INC (CYCC)       0.7302  -0.04 (-5.17%)

0.7302  -0.04 (-5.17%)

US23254L6039 - Common Stock - After market: 0.736 +0.01 (+0.79%)

CYCLACEL PHARMACEUTICALS INC0.7302

NASDAQ:CYCC (12/6/2022, 7:00:01 PM)-0.04 (-5.17%)

After market: 0.736 +0.01 (+0.79%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 11-09 2022-11-09/amc Earnings (Next) 03-27 2023-03-27
Ins Owners 1.16% Inst Owners 18.77%
Market Cap 9.16M Shares 12.54M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 86
IPO 01-01 1996-01-01

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

CYCC Daily chart

Company Profile

Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Berkeley Heights, New Jersey. The firm is engaged in developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The firm is focused on the field of cancer cell cycle biology with a vision to improve patient healthcare by translating insights in cancer biology into medicines that can overcome resistance and ultimately increase a patient’s overall survival. The firm's pipeline includes Fadraciclib, CYC140 and Sapacitabine. The Fadraciclib is a cyclin dependent kinase (CDK) inhibitor selectively targeting Cyclin Dependent Kinase 2 (CDK2) and Cyclin-dependent kinase 9 (CDK9). The CYC140 is a novel, small molecule, selective and potent PLK-centric inhibitor. The firm's Sapacitabine (CYC682) is an orally available nucleoside analogue with a DNA damage response (DDR) mechanism.

Company Info

CYCLACEL PHARMACEUTICALS INC

200 Connell Dr Ste 1500

Berkeley Heights NEW JERSEY 07922

P: 19085177330.0

CEO: Spiro Rombotis

Employees: 0

Website: http://www.cyclacel.com/

CYCC News

News Imagea month ago - CyclacelCyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

- Oral Fadraciclib Daily Dosing Well Tolerated in 18 Evaluable Patients Treated in Dose-Escalation of Phase 1/2 Trial in Advanced Solid Tumors and Lymphoma...

News Imagea month ago - CyclacelCyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business UpdateNews Imagea month ago - CyclacelCyclacel Pharmaceuticals to Release Third Quarter 2022 Financial Results

BERKELEY HEIGHTS, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a...

News Imagea month ago - CyclacelCyclacel Pharmaceuticals to Release Third Quarter 2022 Financial ResultsNews Imagea month ago - CyclacelCyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022

Daily dosing of fadraciclib was well tolerated; single agent activity observed across multiple tumor types including 2 PRs in T-cell lymphoma patients...

News Imagea month ago - CyclacelCyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022

Daily dosing of fadraciclib was well tolerated; single agent activity observed across multiple tumor types including 2 PRs in T-cell lymphoma patients

CYCC Twits

Here you can normally see the latest stock twits on CYCC, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example